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Abstract
Background: PEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of irinotecan encapsulated
in liposomes. The aims of this study were to investigate the dose-limiting toxicity (DLT), maximum tolerated dose
(MTD) and pharmacokinetics (PK) of PEP02 in combination with 5-FU and LV, in patients with advanced refractory
solid tumors.
Methods: Patients were enrolled in cohorts to receive PEP02 from 60 to 120 mg/m2 (dose expressed as the
irinotecan hydrochloride trihydrate salt) as a 90-min intravenous infusion on day 1, followed by 24 h infusion
of 5-FU 2,000 mg/m2 and LV 200 mg/m2 on days 1 and 8, every 3 weeks.
Results: A total of 16 patients were assigned to four dose levels, 60 (three patients), 80 (six patients), 100
(five patients) and 120 mg/m2 (two patients). DLT was observed in four patients, two at the 100 mg/m2 dose
level (one had grade III infection with hypotension and grade III hemorrhage; the other had grade III diarrhea
and grade IV neutropenia), and two at the 120 mg/m2 dose level (one had grade III diarrhea and grade IV
neutropenia; the other had grade III diarrhea). The MTD of PEP02 was determined as 80 mg/m2. The most
common treatment-related adverse events were nausea (81%), diarrhea (75%) and vomiting (69%). Among the
six patients who received the MTD, one patient exhibited partial response, four patients had stable disease
and one showed progressive disease. Pharmacokinetic data showed that PEP02 had a lower peak plasma
concentration, longer half-life, and increased area under the plasma concentration-time curve from zero to
time t of SN-38 than irinotecan at similar dose level.
Conclusions: The MTD of PEP02 on day 1 in combination with 24-h infusion of 5-FU and LV on days 1 and
8, every 3 weeks was 80 mg/m2, which will be the recommended dose for future studies.
Trial registration: The trial was retrospectively registered (NCT02884128) with date of registration: August 12, 2016.
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Background
PEP02 (also known as MM-398, nal-IRI) is an encapsu-
lated nanoliposomal formulation of irinotecan hydro-
chloride (CPT-11) [1]. Irinotecan is a water-soluble
semi-synthetic analogue of the natural alkaloid, camp-
tothecin. It prevents DNA from unwinding and replica-
tion by inhibition of topoisomerase-I, and has already
been approved for use worldwide. However, at higher
dosage, irinotecan causes severe diarrhea and myelosup-
pression, which limits its therapeutic index. The thera-
peutic benefits of encapsulating anti-cancer drugs such
as daunorubicin, doxorubicin and cytarabine in lipo-
somes have been documented [2]. An appropriately de-
signed liposome formulation may reduce the toxicity of
cytotoxic agents to healthy tissues while maintaining its
anti-tumor potency, which in turn improves treatment
efficacy.
In our previous study, the maximum tolerated dose
(MTD) of PEP02 monotherapy was found to be
120 mg/m2 at 3-week interval with favorable pharma-
cokinetic (PK) parameters of the active metabolite,
SN-38 [3]. The acceptable toxicity profile explains the
beneficial effects of PEP02 in combination with other
cytotoxic agents. Irinotecan in combination with 5-
fluorouracil (5-FU) and leucovorin (LV) is the first-line
or second-line therapy for locally advanced and metastatic
colorectal cancer [4]. A synergistic effect was observed
upon the sequential administration of irinotecan and 5-
FU [5, 6]. On the basis of these results, the combination
of PEP02 with 5-FU and LV is considered a reasonable ap-
proach to enhance their therapeutic efficacy. This Phase I
dose escalation study aimed to investigate the MTD, dose-
limiting toxicity (DLT) and recommended dose of PEP02
in combination with 5-FU and LV.
Irinotecan is converted by carboxylesterases to its po-
tent metabolite, SN-38, which is detoxified in part by
converting to inactive SN-38 glucuronide (SN-38G)
through UDP-glucuronosyl transferase 1A isoforms
(UGT1A) [7]. The activity of UGT1A is related to gene
polymorphism of UGT1A family members. Individuals
with genetic mutations of UGT1A exhibit reduced
glucuronidation of SN-38 and an elevated risk of
neutropenia and diarrhea compared with patients with
wild-type alleles [8]. The correlation of UGT1A
polymorphisms and toxicities is discussed.
Methods
Patient eligibility
This trial was a multi-center, open-label, Phase I, dose es-
calation study of PEP02 (PharmaEngine, Inc., Taipei,
Taiwan) in combination with 5-FU and LV in patients
with advanced solid tumors. The inclusion criteria were as
follows: (1) histologically or cytologically confirmed ad-
vanced solid tumor refractory to standard systemic
chemotherapy; (2) aged between 20 and 70 years; (3)
Eastern Cooperative Oncology Group performance score
(ECOG PS) of 0 or 1; (4) life expectancy ≥ 2 months; (5)
adequate bone marrow, hepatic and renal functions: white
blood cells ≥ 3,000/mm3, absolute neutrophil count ≥
1,500/mm3, platelets ≥ 100,000/mm3, hemoglobin ≥
10 g/dL, serum total bilirubin within normal range,
AST and ALT ≤ 3× upper limit of normal range,
serum creatinine ≤ 1.5 mg/dL and blood urea nitro-
gen ≤ 25 mg/dL; (6) no prior treatment for at least
4 weeks before study initiation, including major sur-
gery, chemotherapy, any investigational products or
radiotherapy (6 weeks for nitrosoureas and mitomycin C);
(7) recovered from all treatment-related toxicities or re-
solved to no greater than grade 1 before enrollment; and
(8) written informed consent.
The exclusion criteria were as follows: (1) known or
suspicious primary or secondary brain tumors; (2)
HBsAg-positive or anti-HCV antibody-positive with
splenomegaly (defined as spleen size > 11 cm measured
in longest diameter by CT scan); (3) uncontrolled active
infection or other concomitant serious disease; (4) preg-
nancy or breast-feeding; (5) previous exposure to irinote-
can; (6) history of allergic reactions to compounds of
similar chemical or biologic composition as PEP02, 5-
FU, or LV. This trial was approved by the independent
ethics committee of each participating institute and the
Department of Health, Executive Yuan, Taiwan, and was
performed in accordance with International Conference
on Harmonization Good Clinical Practice guidelines and
Good Clinical Laboratory Practice.
Treatment and dose escalation schedule
The study had a traditional 3 + 3 design with three-
patient cohorts for each dose level. Dose escalation was
only performed after the successful completion of at
least 1 full 3-week cycle by each patient in the dosing
cohort. If none of the first three patients experienced
DLT, dose escalation was carried out for the next cohort
of patients. If one of three patients developed DLT, the
cohort was expanded to six patients. If two or more pa-
tients experienced any DLT, no more patients were to be
entered at the current dose level and the lower dose
level was to be declared the MTD. The MTD was the
highest dose level with no more than 1 DLT among the
accruals. A minimum of six patients were required to be
tested at the dose level defined as the MTD. The starting
dose of PEP02 was 60 mg/m2 with dose expressing as
the irinotecan hydrochloride trihydrate salt, which was
escalated by increments of 20 mg/m2 between dose
levels. Each patient was assigned to a dose level, and no
intra-patient dose escalation was allowed. 5-FU and LV
were administered at a fixed dose of 2000 and 200 mg/m2,
respectively. PEP02 was administered by intravenous
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infusion over 90 min on Day 1, followed by 24-h intraven-
ous infusion of 5-FU and LV on days 1 and 8 every
3 weeks. Pre-medication included dexamethasone and a
serotonin-antagonist. Prophylactic anti-cholinergic agent
was not administered unless acute cholinergic reaction
was observed in prior cycles of treatment. Anti-diarrhea
agents were started according to the guideline of Ameri-
can Society of Clinical Oncology. Treatment was contin-
ued to a maximum of 6 cycles or until disease
progression, unacceptable toxicity, treatment delay >
2 weeks, or patient’s refusal or death.
Dose modification on day 1 of subsequent cycles was
only applied to PEP02, while the dosage of 5-FU/LV
remained unchanged. All dose modifications were to be
based on the worst proceeding toxicity. For patients who
experienced ≥ grade 3 hematologic or non-hematologic
toxicities, the dose of PEP02 was reduced by one dose
level. In addition, the dose of 5-FU on day 8 of each
cycle could be adjusted according to the laboratory data
before the dosing. If the absolute neutrophil count
(ANC) is between 1,000 and 1,499/μL, platelet count is
between 50,000 and 99,999/μL, or diarrhea of grade 2 se-
verity is observed, the dose of 5-FU could be decreased by
25%. 5-FU was withheld when ANC < 999/μL, platelet
count < 50,000/μL or grade 3 diarrhea was observed. The
conditions for the administration of the next cycle of
treatment were ANC ≥ 1,500/μL, platelet counts ≥
100,000/μL, serum creatinine ≤ 1.5 mg/dL, and full reso-
lution of gastrointestinal toxicities.
Definition of dose-limiting toxicity (DLT)
Toxicities were assessed according to the National Can-
cer Institute’s CTCAE version 3.0 (CTCAE, v3). DLT
was defined as occurrence of 1 or more of the following
events attributable to the study drugs during the first
cycle: (1) grade III or IV non-hematological toxicity, ex-
cept grade III nausea, vomiting, or anorexia; (2) grade IV
hematologic toxicity lasting for ≥3 days; (3) grade III
hematologic toxicity associated with complications (e.g.
neutropenic fever or bleeding); (4) dose delay of more
than 2 weeks owing to drug-related toxicity. In addition,
hematological assessment was performed daily whenever
grade IV hematological toxicity occurred.
Patient evaluation
Pretreatment evaluations included medical history, phys-
ical examination, performance status, complete blood
count, hepatic and renal functions and serology of HBsAg
and anti-HCV antibody. Patients were evaluated weekly
with complete blood count and biochemistry analysis.
Radiologic studies to assess response were performed at
baseline and then every 2 cycles of therapy according to
the guidelines of Responses Evaluation Criteria in Solid
Tumors criteria version 1.0. All complete and partial
responses required confirmation by two consecutive ob-
servations at least 4 weeks apart.
Pharmacokinetic sampling and analyzing
During the first cycle of treatment, blood samples were
collected before treatment, during the infusion at 30 and
60 min, at the end of infusion, at1, 3, 9, 24, 48, 72 and
168 h after the end of infusion, and before the second
cycle. Plasma levels of irinotecan and SN-38 were mea-
sured by validated LC/MS/MS analytical methods. The
peak plasma concentration (Cmax), time at which Cmax
occurred (Tmax), elimination half-life (t1/2), area under
the plasma concentration-time curve from zero to time t
(AUC0→t), AUC through infinite time (AUC0→∞), and
clearance (CL) were calculated. Pharmacokinetic param-
eters of individual data set were analyzed by a non-
compartmental model by using WinNonlin™ (Centara,
St. Louis, MO).
Pharmacogenetic studies
Additional 5 mL blood sample was collected into a PAX-
gene vacutainer tube and DNA was extracted using a
DNA purification kit. Fragment analysis was used for
the detection of short tandem repeat polymorphism.
The TaqMan-Allelic discrimination method or direct se-
quencing was used for the detection of single nucleotide
polymorphisms, including UGT1A1*28 and UGT1A1*6.
Statistical analysis
The statistical analysis was descriptive and any inferen-
tial statistics was exploratory in nature. Summary statis-
tics were provided for all efficacy, pharmacokinetic,
pharmacogenetic, safety and baseline/demographic vari-
ables. For categorical variables, frequency tables includ-
ing percentages were presented. For continuous
variables, descriptive statistics such as number of avail-
able observations, mean with standard deviation (STD),
minimum, and maximum were tabulated.
Results
Patient characteristics, dose escalation, DLT and MTD
Between March 2006 and August 2008, a total of 16 pa-
tients (seven men and nine women) were enrolled. The
demographics and baseline characteristics of all patients
are summarized in Table 1. The median age was 49 years
(range: 30–67 years). The most common primary tumors
were pancreatic, stomach, and breast carcinomas. Other
tumor types included keratinizing squamous cell carcin-
oma, cervical cancer and nasopharyngeal carcinoma. A
total of 66 cycles of treatment were initiated, with an
average of 4.1 cycles per patient (range: 1–6 cycles).
There were seven patients (43.8%) completed all 6 cycles
of treatment.
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The dose escalation schedule is outlined in Table 2.
These patients were assigned to four dose levels, with
three, six, five and two patients in dose level I, II, III,
and IV, respectively. At first, none of the first three pa-
tients experienced DLT at dose level I, II, and III; there-
fore, the dose level was further escalated to 120 mg/m2.
Because both of the initial two patients at 120 mg/m2
level experienced DLT during the first cycle of treatment
(one had grade III diarrhea and grade IV neutropenia;
the other had grade III diarrhea), three additional pa-
tients were recruited at the prior dose level, 100 mg/m2.
However, both of the two newly accrued patients at
100 mg/m2 level experienced DLTs (one had grade III
infection with hypotension and grade III hemorrhage;
the other had grade III diarrhea and grade IV neutro-
penia), resulting in 2 episodes of DLT among the five pa-
tients at this dose level. Therefore, the tested dose level
was further de-escalated to 80 mg/m2. Since none of the
patients experienced any DLT, 80 mg/m2 of PEP02 by
90-min intravenous infusion was determined as the
MTD in combination with weekly infusion of 5-FU/LV
on days 1 and 8 of a 21-day cycle.
Toxicity
All 16 patients were assessed for toxicity. Table 3 sum-
marizes the therapy-induced toxicity during treatment.
There were three (18.4%) patients had grade III or above
adverse events (AEs), and 13 and 0.2% of AEs led to dos-
ing delay/reduction and permanent discontinuation of
treatment, respectively. No treatment-related death was
reported in the study.
The most common treatment-related AEs included
nausea (81.3% in incidence), followed by diarrhea
(75.0%), vomiting (68.8%), fatigue (43.8%), mucositis
(mucosa inflammation, 43.8%), leucopenia (37.5%), neu-
tropenia (37.5%), weight loss (37.5%), anemia (31.3%),
and alopecia (31.3%). Acute cholinergic reaction was
rarely observed. Compared with the entire safety popula-
tion, patients who received 80 mg/m2, the MTD dose of
PEP02 experienced less treatment-related AEs (51.1%
versus 57.6%), as well as grade III or above AEs (10.6%
versus 18.4%).
Pharmacokinetics and exploratory pharmacogenetic
studies
The PK of PEP02 is shown in Table 4, Fig. 1a and b.
CPT-11 and SN-38 were characterized for PEP02 single
dose PK at dose levels of 60, 80, 100, and 120 mg/m2 by
90-min intravenous infusion. Changes in the plasma
concentration of CPT-11 showed almost the same pat-
tern at all levels. All concentration curves of plasma
CPT-11 peaked quickly and reached the maximum
around 1 h after the end of PEP02 infusion and grad-
ually dropped in a mono-exponential pattern until the
last sampling point, which was similar to that observed
for PEP02 monotherapy in a previous study [3]. At the
MTD of PEP02, the Cmax of SN-38 was lower (7.98
± 4.39 ng/ml) than that of the conventional formula-
tion of irinotecan at 125 mg/m2 (26.3 ± 11.9 ng/ml),
whereas the AUC of SN-38 was higher than that of
irinotecan (AUC0→ t: 343.36 ± 133.24 ng/ml*h vs.
229 ± 108 ng/mL*h). The t1/2 of SN-38 at the MTD
of PEP02 was 57.54 ± 17.81 h, which was relatively
longer than that of the conventional formulation
(10.4 ± 3.1 h). No statistically significant difference
was observed in the mean values of all pharmacoki-
netic parameters of SN-38 among the 4 dose levels.
The majority of subjects showed wild type alleles for
UGT1A1*28 (TA6TA6: 88%) and UGT1A1*6 (GG: 69%).
No subject harbored homozygous mutation in
UGT1A1*28 or UGT1A1*6 allele. Two and five patients
had heterozygous UGT1A1*28 and UGT1A1*6, respect-
ively. Of which, one patient with heterozygous
Table 1 Patient characteristics












Breast cancer 4 (25)
Pancreatic cancer 5 (31)






Abbreviation: ECOG Eastern Cooperative Oncology Group
Table 2 Dose escalation scheme
Dose Level PEP02 (mg/m2) No. patients No. patients with DLT
I 60 3 0
II 80 3 + 3 0 + 0
III 100 3 + 2 0 + 2
IV 120 2 2
Abbreviation: DLT dose-limiting toxicity
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UGT1A1*28 and UGT1A1*6 experienced grade IV neu-
tropenia and grade III diarrhea, and had the largest
dose-normalized AUC of SN-38. Four out of the 5 sub-
jects with heterozygous UGT1A1*6 possessed relatively
higher dose-normalized AUC of SN-38 comparing to
other subjects; of which 3 patients experienced grade III
toxicities.
Antitumor activity
One patient at dose level III, who suffered from DLT did
not complete at least one post-treatment tumor assessment.
Among the 15 efficacy evaluable patients, two (13.3%) had
confirmed partial response (PR) and nine (60%) had stable
disease (SD), leading to the overall disease control rate
(DCR) of 73.3%. At the MTD of 80 mg/m2, 1 PR and 4
SD were observed among six patients. The tumor
response rate and the disease control rate were 16.7
and 83.3%, respectively. PR was observed in one gastric
cancer patient (at the 80 mg/m2 dose level) and one
breast cancer patient (at the 100 mg/m2 dose level).
Discussion
The current study evaluated the safety profile and pre-
liminary efficacy of PEP02 in combination with 5-FU
Table 3 Treatment-emergent AEs with maximum CTC grade by dose level (incidence ≥ 20%)








AE All grade Grade 3–4
Anemia 7 (43.8%) 0 0 2 (40%) 0
Leukopenia 6 (37.5%) 0 0 2 (40%) 1 (50%)
Neutropenia 6 (37.5%) 1 (33.3%) 1 (16.7%) 2 (40%) 1 (50%)
Abdominal pain 7 (43.8%) 0 0 1 (20%) 1 (50%)
Diarrhea 12 (75.0%) 0 1 (16.7%) 2 (40%) 2 (100%)
Nausea 13 (81.3%) 0 1 (16.7%) 0 0
Vomiting 12 (75.0%) 0 1 (16.7%) 0 0
Fatigue 8 (50.0%) 0 0 1 (20%) 0
Infection 6 (37.5%) 0 0 2 (40%) 1 (50%)
Anorexia 4 (25.0%) 0 0 1 (20%) 0
Hypoalbuminemia 4 (25.0%) 0 1 (16.7%) 0 0
Hypokalemia 8 (50.0%) 1 (33.3%) 2 (33.3%) 2 (40%) 1 (50%)
Hyponatremia 4 (25.0%) 0 0 1 (20%) 1 (50%)
Cough 5 (31.3%) 1 (33.3%) 0 0 0
Abbreviation: AE adverse event


























Total CPT-11 60, N = 3 28.9 ± 15.8 2.4 ± 0.7 1047 ± 1210 1047 ± 1210 2.80 ± 1.59 136 ± 116 21.1 ± 11.7
80, N = 6 29.2 ± 5.2 2.1 ± 0.7 1096 ± 834 1151 ± 880 3.39 ± 0.74 124 ± 106 33.3 ± 15.1
100, N = 5 44.1 ± 7.7 4.0 ± 3.8 2237 ± 1090 2289 ± 1119 2.86 ± 0.75 58 ± 37 43.17 ± 4.8
120, N = 2 47.9 ± 16.2 2.3 ± 0.9 1254 ± 553 1254 ± 553 3.95 ± 0.83 106 ± 47 54.4 ± 17.4
SN-38 60, N = 3 7.02 ± 5.64 13.1 ± 11.7 364 ± 222 1370 ± 1122 NA NA 183.8 ± 172.3
80, N = 6 7.98 ± 4.39 13.3 ± 18.3 343 ± 133 505 ± 165 NA NA 57.5 ± 17.8
100, N = 5 7.39 ± 1.68 12.2 ± 12.3 539 ± 368 840 ± 433 NA NA 73.4 ± 18.3
120, N = 2 7.26 ± 3.90 37.8 ± 17.2 353 ± 164 305 NA NA 30.8
Irinotecana 26.3 ± 11.9 NA 229 ± 108 NA NA NA 10.4 ± 3.1
Mean ± STD; Cmax, peak concentration in plasma; Tmax, time to achieve peak plasma concentration; AUC0→169.5 and AUC0→∞, area under the plasma concentration-time
curve from time zero to 169.5 h and infinity, respectively; Vss, volume of distribution at steady state; t1/2, plasma terminal elimination half-life; Cl, total clearance of drug
from plasma; NA, not available
aIrinotecan 125 mg/m2, package inset of Campto®
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and LV, in patients with refractory advanced malignancy.
Gastrointestinal toxicities and myelosuppression were
the major DLTs, which were comparable to those of free
irinotecan and PEP02 monotherapy [3, 9]. The MTD
(80 mg/m2) of PEP02, in combination with infusion of
5-FU and LV on days 1 and 8 of every-3-week schedule
is recommended for the future studies. In a previous
study, the MTD of PEP02 monotherapy with a 3-week
interval was 120 mg/m2 [3]. The favorable toxicity pro-
files of PEP02 made it a better agent to combine with
other cytotoxic agents. 5-FU/LV in combination with iri-
notecan was the first line treatment of colorectal cancer,
which explains our interest in the evaluation of PEP02 in
combination with 5-FU/LV. The dose of weekly 5-FU in
this study was fixed as 2000 mg/m2, which mimicked
the AIO regimen commonly used in Europe and Asia
[10, 11]. The percentage of grade III or above AEs or all
treatment-related AEs in the MTD group was lower
than that in the overall safety population. For
hematologic laboratory parameters, nadir was observed
between days 13 and 16 after PEP02 administration;
however blood biochemistry was mostly unaffected.
These tolerable and manageable hematological and non-
hematological toxicities indicated that this combination
therapy is feasible for further application.
PEP02 affected the PK characteristics of irinotecan.
Compared to the data of 125 mg/m2 free-form irinote-
can, 80 mg/m2 of PEP02 showed lower Cmax (8.0 ±
4.4 ng/mL vs. 26.3 ± 11.9 ng/mL), longer terminal t1/2
(57.5 ± 17.8 h vs. 10.4 ± 3.1 h) and higher AUC (343 ±
133 ng/mL*hr vs. 229 ± 108 ng/mL*hr) of SN-38 [12, 13].
These favorable PK parameters indicated that PEP02
Fig. 1 Plasma concentration-time profiles of a CPT-11 and b SN-38 at different PEP02 doses
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could decrease the influx of SN-38 from the central com-
partment to the peripheral, leading to less treatment-
related toxicities, even in combination with 5-FU/LV. The
PK data showed the dose-dependent linear distribution of
CPT-11 when study doses were increased from 60 to
120 mg/m2, but no statistically significant difference was
observed in the mean values of pharmacokinetic parame-
ters of CPT-11 and SN-38, including dose-normalized
Cmax, AUC parameters, t1/2, CL, and Vss, possibly owning
to narrow dose increments, small sample size and high
inter-individual variability.
The UGT1A1 gene encoded a varied spectrum of ac-
tive enzymes that are responsible for drug metabolism,
including UGT. The UGT1A1*28 allele is characterized
by the presence of a 7th dinucleotide repeat in the TATA
box of the promoter region, compared to the UGT1A1*1
allele with 6 repeats. This increased number of repeats
results in the reduction in the expression of UGT, lead-
ing to decreased SN-38 detoxification and prolonged ex-
posure time of SN-38 in the intestines. Thus, patients
with homozygous or heterozygous UGT1A1*28 and
treated with irinotecan commonly developed dose limit-
ing neutropenia and late diarrhea [14]. Similar to
UGT1A1*28 polymorphism, the UGT1A1*6 allele also
can decrease the activity of the enzyme in the heterozy-
gous or homozygous genotype. It has been reported that
patients with both UGT1A1*28 and UGT1A1*6 hetero-
zygosity were at high risk to develop irinotecan-related
toxicities [15, 16]. In our study, owning to the small
sample size, a clear correlation cannot be obtained be-
tween polymorphism of UGT1A family genes and phar-
macokinetic parameters or toxicity of PEP02. However,
one subject with heterozygous mutation in both
UGT1A1*6 and UGT1A1*28 had the highest dose-
normalized AUC of SN-38 and experienced grade IV
neutropenia and grade III diarrhea. To draw any firm
conclusions, a PK/PD study according to polymorphism
of UGT1A family genes should be performed [17].
With the limitation of being a very small sample size
study of 15 efficacy evaluable population, two subjects had
confirmed PR and nine subjects had SD as their best-ever
responses during this study period. The tumor response
rate and disease control rate were 13 and 73%, respect-
ively. In a Phase I trial, clinical efficacy cannot be defined
accurately because of heterogeneous tumor types and dif-
ferent dose levels. Of the evaluable patients, PR was noted
in a heavily treated breast cancer patient and a gastric can-
cer patient, and four out of five patients with pancreatic
cancer had SD, implying that this combination regimen is
worthy of further investigation. Indeed, PEP02 either alone
or in combination with 5-FU/LV was investigated in a
phase II PEP0208 study [18] and a phase III NAPOLI-1
study [19] in metastatic pancreatic cancer patients who
progressed after gemcitabine-containing regimen. The
NAPOLI-1 study formed the basis for the regulatory ap-
provals of PEP02 (Irinotecan liposome injection) by the
Taiwan FDA and US FDA in October 2015.
Conclusions
This is the first trial to apply PEP02 in combination with
5-FU and LV in patients with solid tumors, and major
treatment-related DLTs were myelosuppression and diar-
rhea. PEP02 had a lower Cmax, longer t1/2 and increased
AUC0→t of SN-38 compared to irinotecan; similar re-
sults were observed in another study on PEP02 infusion
alone. The dose of 80 mg/m2 of PEP02 in combination
with D1 and D8 infusion of 5-FU/LV with every-3-week
schedule is recommended for future studies.
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